Efficacy of filgotinib on disease activity, including objective signs of inflammation, across the full spectrum of axial spondyloarthritis: 52-week results from the Phase 3 OLINGUITO trial

Jyseleca (filgotinib) - Gilead

https://distribution-congress.eular.org/from.storage?image=15rRXWmdOAJ77zPlkD-rQg8emweHz_0YKsx4A81TaFYsy9vCQvYsUJs2ImftCOhu0

Filip Van den Bosch1, 2; Victoria Navarro-Compán3; Karl Gaffney4; Sofia Ramiro 5; Lien Gheyle 6; Alexandra Mangili7; Karine Muller6; Sole Romero Duran8; Xenofon Baraliakos9

May 23, 2026